

Board of Directors – Meeting held in Public

12 January 2023

Paper title:	Care Quality Commission Update and Developments	Agenda Item 13
Presented by:	Phillipa Hubbard, Director of Nursing, Professions and Care Standards, Deputy Chief Executive, DIPC	
Prepared by:	Beverley Fearnley, Deputy Director of Patient Safety, Compliance and Risk	
Committees where content has been discussed previously	N/A	
Purpose of the paper Please check ONE box only:	<input type="checkbox"/> For approval <input checked="" type="checkbox"/> For information <input type="checkbox"/> For discussion	
Link to Trust Strategic Vision Please check ALL that apply	<input checked="" type="checkbox"/> Providing excellent quality services and seamless access <input type="checkbox"/> Creating the best place to work <input type="checkbox"/> Supporting people to live to their fullest potential <input type="checkbox"/> Financial sustainability, growth and innovation <input checked="" type="checkbox"/> Governance and well-led	
Care Quality Commission domains Please check ALL that apply	<input checked="" type="checkbox"/> Safe <input checked="" type="checkbox"/> Caring <input checked="" type="checkbox"/> Effective <input checked="" type="checkbox"/> Well-Led <input checked="" type="checkbox"/> Responsive	

Purpose of the report

The purpose of this report is to provide Board with an overview of recent CQC activity that is not held within other reports, such as the Chief Executive’s report or learning reports received by the Quality and Safety Committee.

Executive Summary

Medicines Optimisation Pilot

The CQC attended onsite on 22nd and 23rd November to undertake an inspection looking specifically at medicines optimisation. They attended both hospital sites and a number of community venues.

The trust has yet to receive the outcome report from this visit but feedback on the day was largely positive. Some areas of learning were identified but these were areas we were already aware of.

Routine engagement meetings Since our last report we have had one quarterly engagement meeting with the CQC. This happened on 12 December 2022. The meeting followed the usual agenda, with specific consideration being given to winter preparedness and the trust's response to the industrial action taking place	
Do the recommendations in this paper have any impact upon the requirements of the protected groups identified by the Equality Act?	<input type="checkbox"/> Yes (please set out in your paper what action has been taken to address this) <input checked="" type="checkbox"/> No

Recommendation(s)
The Board of Directors is asked to: <ul style="list-style-type: none"> • Note the initial positive feedback from the Medicines optimisation pilot • Note the position with our ongoing relationship with the CQC

Relationship to the Board Assurance Framework (BAF)	
The work contained with this report links to the following strategic risks as identified in the BAF: <ul style="list-style-type: none"> <input type="checkbox"/> SO1: Engaging with our patients, service users and wider community to ensure they are equal partners in care delivery (QSC) <input type="checkbox"/> SO2: Prioritising our people, ensuring they have the tools, skills and right environment to be effective leaders with a culture that is open, compassionate, improvement-focused and inclusive culture (WEC) <input checked="" type="checkbox"/> SO3: Maximising the potential of services to delivery outstanding care to our communities (QSC) <input type="checkbox"/> SO4: Collaborating to drive innovation and transformation, enabling us to deliver against local and national ambitions (Board) <input type="checkbox"/> SO5: To make effective use of our resources to ensure services are environmentally and financially sustainable and resilient (FBIC) <input type="checkbox"/> SO6: To make progress in implementing our digital strategy to support our ambition to become a digital leader in the NHS (FBIC) 	
Links to the Strategic Organisational Risk register (SORR)	The work contained with this report links to the following corporate risks as identified in the SORR: <ul style="list-style-type: none"> • 2417: Ability to meeting regulatory requirements
Compliance & regulatory implications	The following compliance and regulatory implications have been identified as a result of the work outlined in this report: <ul style="list-style-type: none"> • Regulation 9, 12, 17 and 20

The Board of Directors - Public

12 January 2022

CQC Updates and Developments

1 Purpose

The purpose of this report is to provide Board with an overview of recent CQC activity that is not held within other reports, such as the Chief Executive's report or learning reports received by the Quality and Safety Committee

2 Medicines Optimisation Pilot

As previously notified to the Board at November's meeting, the trust has participated in a pilot inspection from CQC looking specifically at medicines optimisation. The CQC attended onsite on 22nd and 23rd November. They attended both hospital sites and a number of community venues.

As well as inspecting clinical sites and engaging with both clinical staff and pharmacy staff, they also met with the Director of Nursing, Professions and Care Standards and the Medical Director as part of the well-led aspect of the evaluation. The inspection was also supported by a data request with 34 individual lines of enquiry.

The trust has yet to receive the outcome report from this visit but feedback on the day was largely positive. Some areas of learning were identified but these were areas we were already aware of.

We will provide a more detailed update once the report has been received. Whilst this will contain feedback and learning, it will not contribute to our trust rating from CQC due to this being a pilot inspection.

3 Routine engagement meetings

Since our last update, we have had one quarterly engagement meeting with the CQC. This happened on 12 December 2022 and was chaired by our interim Inspection Manager. The meeting followed the usual agenda, with specific consideration being given to winter preparedness and the trust's response to the industrial action taking place. The next meeting is due to happen in March 2023.

It is of note that our current interim Inspection Manager left at the end of December 2022 and further interim arrangements are in place whilst the CQC moves towards its new operational models and structures.

4 Recommendations

The Board of Directors is asked to:

- Note the initial positive feedback from the Medicines optimisation pilot
- Note the position with our ongoing relationship with the CQC

Beverley Fearnley

Deputy Director of Patient Safety, Compliance and Risk

22 December 2022